5β-Dihydrotestosterone

From Wikipedia, the free encyclopedia
Not to be confused with 5α-Dihydrotestosterone.
5β-Dihydrotestosterone
5β-Dihydrotestosterone.svg
Names
Preferred IUPAC name
(1S,3aS,3bR,5aR,9aS,9bS,11aS)-1-Hydroxy-9a,11a-dimethylhexadecahydro-7H-cyclopenta[a]phenanthren-7-one
Other names
5β-Androstan-17β-ol-3-one; Etiocholan-17β-ol-3-one; 5β-Dihydrotestosterone; 5β-DHT
Identifiers
3D model (JSmol)
ChEBI
ChEMBL
ChemSpider
ECHA InfoCard 100.164.933 Edit this at Wikidata
  • C[C@]12CCC(=O)C[C@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@H]4O)C
Properties
C19H30O2
Molar mass 290.447 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

5β-Dihydrotestosterone (5β-DHT), also known as 5β-androstan-17β-ol-3-one or as etiocholan-17β-ol-3-one, is an etiocholane (5β-androstane) steroid as well as an inactive metabolite of testosterone formed by 5β-reductase in the liver and bone marrow[1][2] and an intermediate in the formation of 3α,5β-androstanediol and 3β,5β-androstanediol (by 3α- and 3β-hydroxysteroid dehydrogenase) and, from them, respectively, etiocholanolone and epietiocholanolone (by 17β-hydroxysteroid dehydrogenase).[3][4] Unlike its isomer 5α-dihydrotestosterone (5α-DHT or simply DHT), 5β-DHT either does not bind to or binds only very weakly to the androgen receptor.[1] 5β-DHT is notable among metabolites of testosterone in that, due to the fusion of the A and B rings in the cis orientation, it has an extremely angular molecular shape, and this could be related to its lack of androgenic activity.[5] 5β-DHT, unlike 5α-DHT, is also inactive in terms of neurosteroid activity,[6][7] although its metabolite, etiocholanolone, does possess such activity.[8][9]

See also[]

References[]

  1. ^ a b Hormones, Brain and Behavior Online. Academic Press. 18 June 2002. pp. 2262–. ISBN 978-0-08-088783-8.
  2. ^ H.-J. Bandmann; R. Breit; E. Perwein (6 December 2012). Klinefelter's Syndrome. Springer Science & Business Media. pp. 293–. ISBN 978-3-642-69644-2.
  3. ^ Shlomo Melmed; Kenneth S. Polonsky; P. Reed Larsen; Henry M. Kronenberg (30 November 2015). Williams Textbook of Endocrinology. Elsevier Health Sciences. pp. 711–. ISBN 978-0-323-29738-7.
  4. ^ Anita H. Payne; Matthew P. Hardy (28 October 2007). The Leydig Cell in Health and Disease. Springer Science & Business Media. pp. 186–. ISBN 978-1-59745-453-7.
  5. ^ B.A. Cooke; H.J. Van Der Molen; R.J.B. King (1 November 1988). Hormones and their Actions. Elsevier. pp. 173–. ISBN 978-0-08-086077-0.
  6. ^ Current Topics in Membranes and Transport. Academic Press. 1 February 1988. pp. 169–. ISBN 978-0-08-058502-4.
  7. ^ Abraham Weizman (1 February 2008). Neuroactive Steroids in Brain Function, Behavior and Neuropsychiatric Disorders: Novel Strategies for Research and Treatment. Springer Science & Business Media. pp. 210–. ISBN 978-1-4020-6854-6.
  8. ^ Li P, Bracamontes J, Katona BW, Covey DF, Steinbach JH, Akk G (June 2007). "Natural and enantiomeric etiocholanolone interact with distinct sites on the rat alpha1beta2gamma2L GABAA receptor". Mol. Pharmacol. 71 (6): 1582–90. doi:10.1124/mol.106.033407. PMC 3788649. PMID 17341652.
  9. ^ Kaminski RM, Marini H, Kim WJ, Rogawski MA (June 2005). "Anticonvulsant activity of androsterone and etiocholanolone". Epilepsia. 46 (6): 819–27. doi:10.1111/j.1528-1167.2005.00705.x. PMC 1181535. PMID 15946323.


Retrieved from ""